Alpha-1 adrenergic antagonists and the risk of hospitalization or death in non-hospitalized patients with COVID-19

A population-based study

Alpha-1 receptor antagonists are a safe and inexpensive class of drugs used by millions of patients worldwide for the treatment of hypertension and non-cancerous enlarged prostate.

This study examined the association between alpha-1 antagonist exposure and the 30-day risk of hospitalization (hospital admission or emergency department visit) or death in non-hospitalized patients with COVID-19.

Access the full article and associated resources:

Date Released: April 4, 2024

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.